Adesão à Terapia Hormonal Adjuvante com Tamoxifeno e Anastrozol utilizando ARMS-12 e MMAS-4

Autor: Lorena Oliveira de Botelho, Adriana Sañudo, Gil Facina, Gabriela Arantes Wagner

Publikováno v: Revista Brasileira de Cancerologia, Vol 68, Iss 2 (2022)

Introdução: Entre os canceres de mama, aproximadamente 75% das mulheres são receptores hormonais positivos, sendo estas mais propensas a responderem a hormonioterapia com anastrozol e tamoxifeno. Apesar de eficazes, apresentam taxas significativas

Externí odkaz: https://doaj.org/article/5eae29c0b12f49c4af3a7c954f911aa0

Perbedaan β-crosslaps Serum Penderita Karsinoma Payudara Pascamenopause antara yang Diberikan Anastrozol dan Tamoksifen

Autor: Randy Sebastian, Maman Abdurahman, Kiki A. Rizki

Publikováno v: Majalah Kedokteran Bandung, Vol 47, Iss 4, Pp 207-211 (2015)

Tamoxifen and inhibitor aromatases as adjuvant therapy plays an important role in postmenopausal breast cancer patients with positive estrogen receptor. Currently, inhibitor aromatases can replace tamoxifen because it has more advantages than tamoxif

Externí odkaz: https://doaj.org/article/1bacec047e40425f9ce7e089a9c6ceb6

Switching of Hormone Therapies in Breast Cancer Women

Autor: Luana Moreira de Medeiros, Rebeca Stahlschmidt, Amanda Canato Ferracini, Cinthia Madeira de Souza, Cassia Raquel Teatin Juliato, Priscila Gava Mazzola

Publikováno v: Revista Brasileira de Ginecologia e Obstetrícia, Volume: 43, Issue: 3, Pages: 185-189, Published: 24 MAY 2021
Revista Brasileira de Ginecologia e Obstetrícia v.43 n.3 2021
Revista brasileira de ginecologia e obstetrícia
Federação Brasileira das Sociedades de Ginecologia e Obstetrícia (FEBRASGO)
instacron:FEBRASGO
Revista Brasileira de Ginecologia e Obstetrícia, Vol 43, Iss 3, Pp 185-189 (2021)

Objective The objective of the present study was to analyze the reasons that led to hormone therapies (HTs) regimen changes in women with breast cancer. Methods This was a retrospective cross-sectional study from a single-institution Brazilian cancer

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22da34daa7ad039056918d95543d497d
https://doi.org/10.1055/s-0040-1719149

Chemoprophylaxis in ductal carcinoma in situ

Autor: Villalba Ruiz, Lucía

Publikováno v: UCrea Repositorio Abierto de la Universidad de Cantabria
Universidad de Cantabria (UC)

RESUMEN : INTRODUCCIÓN Hasta hace poco a aquellas mujeres diagnosticadas de carcinoma ductal in situ (CDIS) tratadas con cirugía conservadora de mama (BCS) solo se les presentaba la opción de la radioterapia adyuvante para disminuir el riesgo de r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::79e62479295ac2ce04c724f7cd9a56ac
https://hdl.handle.net/10902/26039

Cost-Effectiveness Analysis of Anastrozole versus Tamoxifen in Adjuvant Therapy for Early-Stage Breast Cancer – a Health-Economic Analysis Based on the 100-Month Analysis of the ATAC Trial and the German Health System

Autor: Lux, Michael P., Wöckel, Achim, Benedict, Agnes, Buchholz, Stefan, Kreif, Noémi, Harbeck, Nadia, Kreienberg, Rolf, Kaufmann, Manfred, Beckmann, Matthias W., Jonat, Walter, Hadji, Peyman, Distler, Wolfgang, Raab, Guenther, Tesch, Hans, Weyers, Georg, Possinger, Kurt, Schneeweiss, Andreas

Publikováno v: Onkologie 2010;33:155–166, ISSN: 0378-584X

Background: In the ‘Arimidex’, Tamoxifen Alone or in Combination (ATAC) trial, the aromatase inhibitor (AI) anastrozole had a ignificantly better efficacy and safety profile than tamoxifen as initial adjuvant therapy for hormone receptor-positive

Externí odkaz: https://tud.qucosa.de/id/qucosa%3A27603
https://tud.qucosa.de/api/qucosa%3A27603/attachment/ATT-0/